The fourth patient was an 11-year-old boy with AML FAB M4, mutations in WT1 and FLT3-ITD (allele ratio of 0.54), who relapsed during first-line therapy with 50% blasts in peripheral blood before the last of five courses (AML-BFM 98 trial). This evidence concerns the gene FLT3 and acute myeloid leukemia.